Press Releases

NASDAQ
SPPI
$10.56
--0.35
DAY HI:
$10.90
DAY LOW:
$10.43
VOLUME:
627,759
2:59 PM EST 01/22/19

Press Releases

Date Title View PDF
Oct 10, 2017 Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash
Sep 29, 2017 Spectrum Pharmaceuticals Provides Update on At-The-Market Facility
Sep 28, 2017 Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
Sep 5, 2017 Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Aug 17, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th
Aug 14, 2017 Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Aug 3, 2017 Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update
Aug 1, 2017 Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
Jul 27, 2017 Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast
Jun 19, 2017 Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting
Jun 2, 2017 Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
May 30, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th
May 16, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
May 2, 2017 Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
Apr 27, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
Apr 25, 2017 Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast
Apr 4, 2017 Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
Mar 31, 2017 Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017
Mar 30, 2017 Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 8, 2017 Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
Mar 1, 2017 Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast
Feb 16, 2017 Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd
Dec 8, 2016 Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 6, 2016 Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology (ASH)
Dec 5, 2016 Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Displaying records 51 - 75 of 766